Document is current

Article History

Received: 22 November 2025

Accepted: 4 February 2026

First Online: 1 June 2026

Competing interests

: The authors declare no competing financial or non-financial interests: S Belyew, S Mills, A Santacruz, C Supnet-Bell, BA Gordon, R Hornbeck, L Ibanez, C Xiong. The authors declare the following competing interests: E McDade: EMM has received research support from the National Institutes of Health, the National Institute on Aging (R01AG068319, U19AG032438, U01AG059798), Alzheimer’s Association (DIAN-TU-PP-22-872356, DIAN-TU-TAU-21-822987, DIAN-TU-OLE-21-725093), GHR Foundation, an anonymous organization, Knight Family, and the DIAN-TU Pharma Consortium (Biogen, Eisai, Eli Lilly and Company/Avid Radiopharmaceuticals, F. Hoffman-La Roche/Genentech, and Janssen). He is a co-inventor of the “Methods of diagnosing AD with phosphorylation changes” technology licensed by Washington University to C2N Diagnostics, US Patent 11,085,935 B2, Aug 10, 2021 (Bateman, Barthelemy, McDade, Li). Washington University also holds 5% equity in C2N. Through these relationships, Washington University and EMM are entitled to receive royalties from the license agreement with C2N. He is co-author of the Alzheimer Association’s 2024 Alzheimer’s disease updated diagnostic criteria. He has received travel support from the Alzheimer’s Association for work related to the development of the document. He has served as a consultant, a member of advisory boards, or a DSMB member for Eli Lilly, Alector, Alzamend, Sanofi, AstraZeneca, Hoffman La-Roche, and Merck.A Porsteinsson: Dr. Porsteinsson reports personal fees from Acadia Pharmaceuticals, Athira, Axsome, Biogen, BMS, Cognitive Research Corp, Cognition Therapeutics, Eisai, Eli Lilly, IQVIA, Lundbeck, MapLight Therapeutics, Novartis, Novo Nordisk, Oligomerix, ONO Pharmaceuticals, Otsuka, WCG, WebMD, and Xenon; grants to his institution from Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech/Roche, ONO, Vaccinex, NIA, NIMH, and DOD. He is a member of the Scientific Advisory Board of Alzheon, Athira, Cognition Therapeutics, Cognito, and Oligomerix. He is a member of the Clinical Advisory Board of MapLight Therapeutics.DB Clifford: Dr. Clifford is Medical Director of the Dominantly Inherited Alzheimer Network – Trials Unit (DIAN-TU), supported by NIA. He receives no direct support from Eisai, but Eisai supports DIAN-TU studies supplying investigational products as part of protocols seeking to prevent the onset of dementia in participants at risk due to dominantly inherited Alzheimer disease. Lilly also supplies investigational agents for DIAN-TU studies monitored by Dr Clifford. He has NIH support to study neurotherapeutics, HIV and Alzheimer disease supported by U01AG059798, R01AG068319, R24MH129166, and U24NS107198. He participates in DSMB/PML Adjudication committees work monitoring clinical studies by Wave Pharmaceuticals, Morphic, Sanofi, Teva, Roche, Pfizer, and Avidity.J Llibre-Guerra: JLlG’s research is supported by NIH-NIA (K01AG073526), the Alzheimer’s Association (AARFD-21-851415, SG-20-690363, 24HPE-1287320), the Michael J. Fox Foundation (MJFF-020770), the Foundation for Barnes-Jewish Hospital and the McDonnell Academy.G Wang: Guoqiao Wang, receives research support from the NIH-NIA. He reports serving on a Data Safety Committee for Amydis Corporate, Abata Therapeutics, Skyhawk Therapeutics, and statistical consultant for Eisai inc. and Alector Inc and receives direct payments as part of these roles. Y Li: YL is a co-inventor of the “Methods of diagnosing AD with phosphorylation changes” technology licensed by Washington University to C2N Diagnostics, US Patent 11,085,935 B2, Aug 10, 2021 (Bateman, Barthelemy, McDade, Li). which is of licensed by C2N. She may receive royalties related to the licensing agreement. Additionally, Washington University holds 5% equity with C2N and is entitled to receive royalties under the license agreement. She receives research support from the NIH-NIA.TS Benzinger: Grants or contracts to Washington University: Grants or contracts have been received from the National Institutes of Health (NIH), the Alzheimer’s Association, and the American Society for Neuroradiolgy (ASNR): from Siemens with funds paid to her institution; technology transfer and precursors for radiopharmaceuticals from Avid Radiopharmaceuticals/Eli Lilly, LMI, and Lantheus; scanner loan from Hyperfine to her institution. Personal compensation: Dr. Benzinger has received consulting fees from Biogen, Eli Lilly, Eisai, Bristol Myers Squibb, J&J, and Merck. Dr. Benzinger has received payment for CME activity from Radiology Today, Medscape, PeerView, and Neurology Today. Travel: Dr. Benzinger has received travel support from Janssen, Eisai, Cedars Sinai Medical Center, Hong Kong Neurological Association, the Radiological Society for North America, the American College of Radiology and the Alzheimer’s Association. Unpaid activities: Dr. Benzinger has participated in an Advisory Board for Siemens (no payments). She has served as an external advisor for NIH-funded studies (no payments). She has served as the co-chair of ASNR Alzheimer’s, ARIA and Dementia Study Group, and RSNA Quantitative Imaging Committee (QuIC) (all unpaid). She has served as a committee member of the American College of Radiology/ALZ NET imaging, NIH CNN Study Section Chair, and had a leadership or fiduciary role in the ACR Commission on Neurology (all unpaid). J Hassenstab: Paid consultant for Quanterix, Abbvie, and Prothena. He receives research support from the NIH-NIA.RJ Perrin: R.J.P. is supported by NIH grants R01AG068319, R01 AG053267, P01 AG003991, P30 AG066444, U19 NS110456, U19 AG024904, U19 AG032438, U19 AG07879, U19 AG069701, RF1NS139970, R01 AG074909, R01 AG058676, R01 AG054567, R01 AG052550, R01 AG070883, R01 NS134586, R01NS097799, R01NS092865, and R01 NS075321, by the American Parkinson Disease Association, and by Target ALS. R.J.P.’s laboratory receives cost recovery funding from Biogen for tissue procurement and processing services related to ALS clinical trials. Neither R.J.P. nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company.C Cruchaga: CC is a member of the scientific advisory board of Circular Genomics and owns stocks,and is on the scientific advisory board of ADmit and Alamar for which he receives personal compensation. CC consults for Sanofi, NovoNordisk, and Owkin. CC has received research support from GSK, Danaher and EISAI and the NIH-NIA.A Goate: I serve on the SAB for Genentech and Muna Therapeutics. I have consulted for Merck in the last 36 months for which I receive personal compensation.B Wendelberger: Dr. Wendelberger is a Senior Statistical Scientist at Berry Consultants, LLC, a statistical consulting firm that specializes in the design, conduct, oversight, and analysis of adaptive and platform clinical trials.”A Aschenbrenner: AJA has provided paid consultation to CognitionMetrics, LLC. He receives research support from the NIH-NIA. JC Morris: NIH support: P30 AG066444; P01AG003991; P01AG026276Consulting fees paid to him: Barcelona Brain Research Center (BBRC); Native Alzheimer Disease-Related Resource Center in Minority Aging Research, Ext Adv BoardDSMB or Advisory Board: Cure Alzheimer’s Fund, Research Strategy Council; LEADS Advisory Board, Indiana UniversityDM Holtzman: DMH co-founded, has equity, and is on the scientific advisory board of C2N Diagnostics. DMH is on the scientific advisory boards of Denali, Genentech, Cajal Neuroscience, and Switch and consults for Asteroid, Pfizer, Novartis, and Roche. RJ Bateman: RJB has received research support from the National Institutes of Health, the National Institute on Aging, Alzheimer’s Association, GHR Foundation, an anonymous organization and the DIAN-TU Pharma Consortium Biogen, Eisai, Eli Lilly and Company/Avid Radiopharmaceuticals, F. Hoffman-La Roche/Genentech, and Janssen. He has also received funding from Eisai, Avid Radiopharmaceuticals, Janssen, Cogstate, Cerveau, and Signant Health, AbbVie, Bristol Myers Squibb, and Novartis. RJB co-founded C2N Diagnostics, which offers the PrecivityAD2 blood test. Washington University and RJB have equity ownership interest in C2N Diagnostics and receive income based on technology and receives income from C2N Diagnostics for serving on the scientific advisory board. He has served as an unpaid member of advisory boards for Roche and Biogen.